Is Pfizer the Best Stock in Its Sector? A Look at the Numbers

Is Pfizer the best stock in its sector? The stock trades on the NSE at Rs 3,836 as of 05 October 2026, within its 52-week range of Rs 3,792.10 to Rs 5,578.50. Pfizer Ltd is the listed Indian arm of Pfizer Inc and sells prescription pharmaceuticals and vaccines in India.

Pfizer sits in the Healthcare sector, and its 17.19% ROE and 23.99x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Pfizer

Pfizer Ltd is the listed Indian arm of Pfizer Inc and sells prescription pharmaceuticals and vaccines in India. The stock is trading near its 52-week low, about 31 percent below its high, and it trades at a high absolute share price. At a market capitalisation of Rs 17,636 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Pfizer the Best Stock in Its Sector?

Pfizer makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 17.19% ROE with a 23.99x P/E against the sector's 50.45x Industry P/E. Pfizer's 23.99x P/E is far below the 50.45x Industry P/E despite a strong 17.19% ROE and a 1.95% dividend yield, making it look inexpensive relative to its own quality, though the stock is trading near its 52-week low, about 31 percent below its high.

Metric	Pfizer
CMP (NSE)	Rs 3,836.00
52-Week High / Low	Rs 5,578.50 / Rs 3,792.10
Market Cap	Rs 17,636 Cr
P/E (TTM) vs Industry P/E	23.99x vs 50.45x
P/B	4.20
ROE	17.19%
EPS (TTM)	Rs 160.70
Dividend Yield	1.95%
Debt to Equity	0.02

Compare Pfizer Against Other Healthcare Sector Stocks

How Pfizer Compares Against Its Healthcare Sector Peers

The table below sets Pfizer against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Pfizer	17,636	23.99	17.19%	0.02
Neuland Laboratories	27,580	55.41	19.42%	0.16
Lincoln Pharmaceuticals	1,172	12.15	11.60%	0.01
Peer average (2 companies)	-	33.78	15.51%	0.09

Against this peer set, Pfizer's 17.19% ROE is above the 15.51% peer average, and its P/E of 23.99x runs below the peer average of 33.78x. Pfizer's 23.99x P/E is far below the 50.45x Industry P/E despite a strong 17.19% ROE and a 1.95% dividend yield, making it look inexpensive relative to its own quality, though the stock is trading near its 52-week low, about 31 percent below its high.

What Makes Pfizer Worth Watching in Healthcare

• Strong ROE, debt free: A 17.19% ROE alongside a debt to equity ratio of 0.02 reflects an efficient, well-capitalised business.
• Well below Industry P/E: A 23.99x P/E against a 50.45x Industry P/E is a wide discount for a business with a strong ROE.
• Dividend yield: A 1.95% dividend yield adds a meaningful income component.

Pfizer Valuation: Is It Justified?

Pfizer's 23.99x P/E is far below the 50.45x Industry P/E despite a strong 17.19% ROE and a 1.95% dividend yield, making it look inexpensive relative to its own quality, though the stock is trading near its 52-week low, about 31 percent below its high. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Patel Retail the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Pfizer and other Healthcare sector stocks.

How to Track Pfizer Before You Invest

Before deciding whether Pfizer deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Pfizer to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Pfizer earns a place in the best stock in its sector conversation on the strength of a 17.19% ROE and a P/E of 23.99x against a 50.45x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Pfizer the best stock in its sector?

Ans. Pfizer has a 17.19% ROE and trades at 23.99x P/E against a 50.45x Industry P/E, and compares above the peer average ROE of 15.51% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Pfizer?

Ans. Pfizer was trading at Rs 3,836.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 3,792.10 to Rs 5,578.50.

What sector does Pfizer belong to?

Ans. Pfizer is classified under the Healthcare sector on Univest.

How does Pfizer compare to its sector peers on P/E?

Ans. Pfizer's P/E of 23.99x is below the 33.78x average of the 2 named peers compared in this article.

What is Pfizer's return on equity?

Ans. Pfizer reported a return on equity of 17.19%, which is above the 15.51% average of its named peers in this comparison.

Should I invest in Pfizer based on its sector position?

Ans. Pfizer's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Pfizer the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Pfizer has a 17.19% ROE and trades at 23.99x P/E against a 50.45x Industry P/E, and compares above the peer average ROE of 15.51% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Pfizer?", "acceptedAnswer": {"@type": "Answer", "text": "Pfizer was trading at Rs 3,836.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 3,792.10 to Rs 5,578.50."}}, {"@type": "Question", "name": "What sector does Pfizer belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Pfizer is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Pfizer compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Pfizer's P/E of 23.99x is below the 33.78x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Pfizer's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Pfizer reported a return on equity of 17.19%, which is above the 15.51% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Pfizer based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Pfizer's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}